RELX Technology's Stock Price Drops in Midday Trading

Business by 2FIRSTS.ai
Dec.22.2023
RELX Technology's Stock Price Drops in Midday Trading
RELX Technology, an e-cigarette manufacturer, saw a 2.9% drop in stock price during Thursday's midday trading.

According to market trading website watchlistnews, the stock price of e-cigarette manufacturer RELX Technology dropped by 2.9% during Thursday's midday trading session. The stock reached a low trading price of $1.94 per share and closed at $1.98 per share. During the midday session, there were a total of 1,728,733 shares traded, which is a 79% decrease compared to the average trading volume of 8,406,188 shares. The previous closing price was $2.04.

 

Over the past 50 days, the average price of the company's stock has been $1.90, while the 200-day moving average price stands at $1.72.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy's Ministry of Enterprises and Made in Italy has submitted a detailed opinion against Ireland's proposed "Public Health (Single Use Vapes) Bill 2025." Italy argued that the comprehensive ban on disposable vapes lacks scientific evidence, violates the EU principle of the free movement of goods, and conflicts with the existing Tobacco Products Directive.
Apr.10 by 2FIRSTS.ai
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
The U.S. Court of Appeals for the Fourth Circuit has declined to grant en banc or other rehearing of its decision to stay an order that had blocked enforcement of certain Virginia e-cigarette regulations. In a brief order filed Tuesday, the court denied a rehearing petition by Nova Distro Inc. and Tobacco Hut and Vape Fairfax Inc., noting that no judge requested a poll on the petition.
Mar.05 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s General Stores (NASDAQ: CASY) reported accelerating growth in modern nicotine products during its fiscal third quarter ended January 31, 2026. Nicotine pouch sales increased 31% year over year, while vapor products rose 12%. Although cigarette unit sales continued to decline, management stated that the rate of decline slowed compared to prior quarters.
Market
Mar.15
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Japan Tobacco Releases Three Ploom AURA Collaboration Panels Inspired by “Sake”
Japan Tobacco Releases Three Ploom AURA Collaboration Panels Inspired by “Sake”
Japan Tobacco announced that it will sponsor “CRAFT SAKE WEEK 2026,” to be held at Roppongi Hills Arena, and set up a dedicated smoking area called “Ploom LOUNGE.” Three Ploom AURA collaboration front panels inspired by the theme of “sake” will be offered at the venue, along with trial use, sales, and related original content.
Apr.13 by 2FIRSTS.ai